1. Home
  2. MCI vs PRTC Comparison

MCI vs PRTC Comparison

Compare MCI & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barings Corporate Investors

MCI

Barings Corporate Investors

HOLD

Current Price

$20.10

Market Cap

426.8M

Sector

Finance

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$16.91

Market Cap

386.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCI
PRTC
Founded
1971
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
426.8M
386.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MCI
PRTC
Price
$20.10
$16.91
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
40.4K
4.8K
Earning Date
01-01-0001
08-28-2025
Dividend Yield
8.46%
N/A
EPS Growth
N/A
N/A
EPS
1.82
0.20
Revenue
N/A
$6,391,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.88
$7.77
Revenue Growth
N/A
1265.60
52 Week Low
$12.96
$13.30
52 Week High
$19.24
$23.35

Technical Indicators

Market Signals
Indicator
MCI
PRTC
Relative Strength Index (RSI) 37.91 51.09
Support Level $20.60 $16.44
Resistance Level $20.83 $17.17
Average True Range (ATR) 0.40 0.35
MACD -0.08 0.12
Stochastic Oscillator 20.25 55.29

Price Performance

Historical Comparison
MCI
PRTC

About MCI Barings Corporate Investors

Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: